GSTM5 and pachyonychia congenita: By examining both GSTM5 expression levels and genetic variants, we aim to gain valuable insights into its role in modulating tumor response to ADT, potentially offering new therapeutic strategies for treatment resistance and improving the clinical management of advanced PC [19].